LEXICON PHARMACEUTICALS, INC. (LXRX): Nasdaq/NYSE listing notice — Lexicon Pharmaceuticals receives Nasdaq bid-price deficiency notice; 180 days to cure

LEXICON PHARMACEUTICALS, INC.

Nasdaq notified Lexicon on Jan 3, 2025 that bid price closed below $1 for 31 consecutive business days.
Company has until July 2, 2025 to regain compliance by closing at $1+ for 10 consecutive days.
If not cured, Lexicon may seek a second 180-day period if it meets other listing standards; reverse split considered.
Notice does not cause immediate delisting; company will monitor and evaluate options.
No assurance that compliance can be regained or maintained.

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.95

LEXICON PHARMACEUTICALS, INC. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5450(a)(1)).

Exchange: nasdaq
Notice: deficiency notice
Deficiency: minimum bid price
Rules: 5450(a)(1)

Exact text from the filing

January 3, 2025, we received a letter (the “Notice”) from the Listing Qualifications staff of The NASDAQ Stock Market LLC (“Nasdaq”) indicating that, based upon the closing bid price of our common stock for the last 31 c

View on SEC.gov

93 listing & compliance notices filed in the last 30 days. Browse all listing & compliance notices →

LEXICON PHARMACEUTICALS, INC. filing history →

Source: SEC EDGAR

accession 0001062822-25-000005

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.